3C PATCH® REIMBURSEMENT
3C Patch® System is an FDA-cleared advanced wound management solution.
Nationally covered by Medicare, read the press release here.
Medicare Code – G0465
ICD 10 – Two diagnosis codes are required – Diabetic Mellitus plus Chronic Ulcer
National Average Payment – $1,739.33
Our reimbursement specialists are available to provide support and answer any questions you might have about coding, billing, and reimbursement. Give us a call or send us an email and we will be happy to assist you.
FOR MORE INFORMATION AND PRODUCT PRICING
Scientific and clinical data support the effect of 3C Patch® in wound management, compared to standard of care.
Effective April 13, 2021, Medicare covers the 3C Patch for the treatment of chronic non-healing diabetic wounds for 20 weeks.
The 3C Patch® System is a single use medical device used to prepare an autologous platelet-rich plasma (PRP) gel from the patient’s peripheral blood by centrifugation, without any reagents. Under the supervision of a healthcare professional, the PRP gel produced by the 3C Patch® System is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and mechanically or surgically-debrided wounds. See 510(k) Summary – BK200471 (accessed Sept. 17, 2021), available at https://www.fda.gov/media/104546/download.
See Medicare Claims Processing Manual, CMS Pub. 100-04: Transmittal 11171, National Coverage Determination
(NCD) 270.3 Blood-Derived Products for Chronic, Non-Healing Wounds (, January 12, 2022), available at https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/R11171CP_1.pdf and Transmittal 11460, June 17, 2022 https://www.cms.gov/files/document/r11460otn.pdf
Current Procedural Terminology (CPT®) copyright 2023 American Medical Association. All rights reserved.
CPT is a registered trademark of the American Medical Association.
2023 Medicare Outpatient Prospective Payment System Final Rule for 2023 www.cms.gov
FDA CLEARANCE
The 3C Patch® System is cleared by the FDA for the management of exuding wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically debrided wounds.
CE MARKED IN EUROPE
The intended use of the 3C Patch® Device is to produce an autologous platelet-rich fibrin patch for wound management of recalcitrant wounds.